$CRSP
CRISPR Therapeutics AG

2021 Q4 Form 10-Q Financial Statement

#000095017021002825 Filed on November 03, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $12.90M $824.0K $148.0K
YoY Change 3386.22% 456.76% -99.93%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.13M $24.35M $21.50M
YoY Change -6.48% 13.27% 38.71%
% of Gross Profit
Research & Development $134.5M $105.3M $71.01M
YoY Change 63.19% 48.32% 24.14%
% of Gross Profit
Depreciation & Amortization $6.261M $5.300M $2.300M
YoY Change 144.57% 130.43% 76.92%
% of Gross Profit
Operating Expenses $158.6M $129.7M $92.55M
YoY Change 46.67% 40.12% 27.19%
Operating Profit -$128.8M -$92.40M
YoY Change 39.45% -166.4%
Interest Expense $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $2.197M $1.101M $160.0K
YoY Change 266.17% 588.13% -134.33%
Pretax Income -$143.5M -$127.7M -$92.24M
YoY Change 33.86% 38.5% -166.5%
Income Tax -$2.253M -$600.0K $200.0K
% Of Pretax Income
Net Earnings -$141.2M -$127.2M -$92.44M
YoY Change 31.96% 37.55% -166.78%
Net Earnings / Revenue -1095.03% -15431.19% -62458.78%
Basic Earnings Per Share -$1.67 -$1.32
Diluted Earnings Per Share -$1.843M -$1.67 -$1.32
COMMON SHARES
Basic Shares Outstanding 76.53M 76.29M 70.14M
Diluted Shares Outstanding 76.29M 70.14M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.329B $1.493B $1.167B
YoY Change 13.66% 27.89% 85.34%
Cash & Equivalents $923.0M $1.012B $1.041B
Short-Term Investments $405.6M $481.1M $125.7M
Other Short-Term Assets $38.08M $41.42M $24.80M
YoY Change 45.9% 67.03% -27.7%
Inventory
Prepaid Expenses
Receivables $305.0K $152.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.418B $2.519B $1.391B
YoY Change 40.83% 81.1% 109.45%
LONG-TERM ASSETS
Property, Plant & Equipment $137.6M $105.9M $37.92M
YoY Change 226.32% 179.2% 79.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $5.291M $4.788M $17.50M
YoY Change 309.2% -72.64% 2519.76%
Total Long-Term Assets $334.4M $302.8M $94.10M
YoY Change 200.29% 221.77% 66.48%
TOTAL ASSETS
Total Short-Term Assets $2.418B $2.519B $1.391B
Total Long-Term Assets $334.4M $302.8M $94.10M
Total Assets $2.752B $2.822B $1.485B
YoY Change 50.54% 90.02% 106.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $14.82M $10.17M $19.00M
YoY Change 62.92% -46.49% 463.13%
Accrued Expenses $91.00M $68.30M $35.45M
YoY Change 69.21% 92.7% 58.26%
Deferred Revenue $1.011M $1.562M
YoY Change -56.81%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $119.9M $96.21M $84.10M
YoY Change 27.18% 14.39% 5.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.339M $8.086M $57.60M
YoY Change -3.81% -85.96% 24410.64%
Total Long-Term Liabilities $7.339M $8.086M $57.60M
YoY Change -3.81% -85.96% 24410.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $119.9M $96.21M $84.10M
Total Long-Term Liabilities $7.339M $8.086M $57.60M
Total Liabilities $352.4M $308.8M $141.7M
YoY Change 115.24% 117.93% 10.09%
SHAREHOLDERS EQUITY
Retained Earnings -$195.9M -$54.67M
YoY Change -65.84%
Common Stock $2.601B $2.568B
YoY Change 16.2%
Preferred Stock
YoY Change
Treasury Stock (at cost) $63.00K $63.00K
YoY Change 0.0%
Treasury Stock Shares $180.3K $180.3K
Shareholders Equity $2.399B $2.513B $1.343B
YoY Change
Total Liabilities & Shareholders Equity $2.752B $2.822B $1.485B
YoY Change 50.54% 90.02% 106.08%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$141.2M -$127.2M -$92.44M
YoY Change 31.96% 37.55% -166.78%
Depreciation, Depletion And Amortization $6.261M $5.300M $2.300M
YoY Change 144.57% 130.43% 76.92%
Cash From Operating Activities -$86.04M -$81.33M -$75.70M
YoY Change 5.93% 7.44% -156.74%
INVESTING ACTIVITIES
Capital Expenditures -$9.183M -$37.05M -$5.520M
YoY Change 47.16% 571.18% 124.39%
Acquisitions
YoY Change
Other Investing Activities $467.0K -$528.1M -$324.8M
YoY Change -100.24% 62.6%
Cash From Investing Activities -$8.716M -$565.2M -$330.3M
YoY Change -95.73% 71.1% 13328.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.299M 10.21M 512.9M
YoY Change -98.47% -98.01% 623.5%
NET CHANGE
Cash From Operating Activities -86.04M -81.33M -75.70M
Cash From Investing Activities -8.716M -565.2M -330.3M
Cash From Financing Activities 6.299M 10.21M 512.9M
Net Change In Cash -88.46M -636.3M 106.9M
YoY Change -169.56% -695.45% -47.06%
FREE CASH FLOW
Cash From Operating Activities -$86.04M -$81.33M -$75.70M
Capital Expenditures -$9.183M -$37.05M -$5.520M
Free Cash Flow -$76.86M -$44.28M -$70.18M
YoY Change 2.5% -36.91% -151.65%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37923
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
dei Entity Central Index Key
EntityCentralIndexKey
0001674416
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Entity Registrant Name
EntityRegistrantName
CRISPR THERAPEUTICS AG
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
V8
dei Entity Address Address Line1
EntityAddressAddressLine1
Baarerstrasse 14
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6300
dei Entity Address City Or Town
EntityAddressCityOrTown
Zug
dei Entity Address Country
EntityAddressCountry
CH
dei City Area Code
CityAreaCode
41 (0)41
dei Local Phone Number
LocalPhoneNumber
561 32 77
dei Security12b Title
Security12bTitle
Common Shares, nominal value CHF 0.03
dei Trading Symbol
TradingSymbol
CRSP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
50865000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4788000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1293000
CY2021Q3 us-gaap Assets
Assets
2821725000
CY2020Q4 us-gaap Assets
Assets
1827966000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10167000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9094000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
68303000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
CY2021Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1562000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2341000
CY2021Q3 us-gaap Taxes Payable Current
TaxesPayableCurrent
3265000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7630000
CY2021Q3 us-gaap Liabilities
Liabilities
308802000
CY2020Q4 us-gaap Liabilities
Liabilities
163732000
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
76526964
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1011548000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1168620000
CY2021Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1465812000
CY2020Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
521713000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
152000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
144000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
41423000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
26143000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
2518935000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
1716620000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105883000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
139000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
180000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
175132000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
10473000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12641000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11362000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
268000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
7207000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
96206000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
94259000
CY2021Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11776000
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
11776000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
192734000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
50067000
CY2021Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8086000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-127748000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2821725000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1827966000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
824000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
62442000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
76643496
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
148000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
902064000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
349000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
105321000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
129673000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
92547000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
74110160
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
76463180
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
73914844
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
2366000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
2277000
CY2021Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
180316
CY2020Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
195316
CY2021Q3 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2020Q4 us-gaap Treasury Stock Value
TreasuryStockValue
63000
CY2021Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2566057000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2235679000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54667000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-573576000
CY2021Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-770000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-83000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2512923000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71008000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
304163000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
184581000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24352000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21539000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
78675000
us-gaap Operating Expenses
OperatingExpenses
382838000
us-gaap Operating Expenses
OperatingExpenses
247023000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-128849000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-92399000
us-gaap Operating Income Loss
OperatingIncomeLoss
519226000
us-gaap Operating Income Loss
OperatingIncomeLoss
-246674000
CY2021Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
1101000
CY2020Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
160000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
3806000
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
5804000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1101000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
160000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3806000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5804000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-92239000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
523032000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-241967000
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.85
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-240870000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-595000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4123000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
956000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-92439000
us-gaap Net Income Loss
NetIncomeLoss
518909000
us-gaap Net Income Loss
NetIncomeLoss
-241826000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-24000
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
31000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
3000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-117000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-144000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-673000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-144000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-127294000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92552000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
518222000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.77
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76288534
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70143481
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75712437
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64159224
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.77
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76288534
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70143481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80554682
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64159224
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
939425000
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1388000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
14151000
CY2020Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
889000
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-25000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-69731000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
886097000
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
82189000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6345000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15697000
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-3000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-79656000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
910670000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
494589000
CY2020Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
12659000
CY2020Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
694000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
17240000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-113000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-92439000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
1343301000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
1664234000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
222175000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
3000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9784000
CY2021Q1 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
751000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22092000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-378000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-113163000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
1805498000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10909000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
28331000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-168000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
759225000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2603795000
CY2021Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
4000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8875000
CY2021Q3 crsp Stock Purchased During Period Value Employee Stock Purchase Plan
StockPurchasedDuringPeriodValueEmployeeStockPurchasePlan
1344000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
26199000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
2512923000
us-gaap Profit Loss
ProfitLoss
518909000
us-gaap Profit Loss
ProfitLoss
-241826000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11692000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
6618000
us-gaap Share Based Compensation
ShareBasedCompensation
76622000
us-gaap Share Based Compensation
ShareBasedCompensation
47088000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-9420000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-979000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
8000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18775000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-19273000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
14733000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
391000
crsp Equity Issuance Costs In Accounts Payable And Accrued Expenses
EquityIssuanceCostsInAccountsPayableAndAccruedExpenses
5955000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
17394000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-779000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-350000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
19679000
crsp Increase Decrease In Operating Lease Assets And Liabilities
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities
-282000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6483000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-6037000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
625010000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-157154000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
72522000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12119000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1386785000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
325316000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
432593000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
509000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1026714000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-336926000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
213267000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
582225000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
31379000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
21300000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
244646000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
603525000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-14000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-157072000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
109450000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1185468000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
948812000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1028396000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1058262000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6264000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
2863000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1011548000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1041417000
CY2021Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16848000
CY2020Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
16845000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1028396000
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1058262000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. </span><span style="background-color:rgba(0,0,0,0);color:rgba(33,37,41,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On an ongoing basis, the Company’s management evaluates its estimates, which include, but are not limited to, revenue recognition, equity-based compensation expense and reported amounts of expenses during the period. Significant estimates in these consolidated financial statements have been made in connection with revenue recognition and equity-based compensation expense. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Changes in estimates are reflected in reported results in the period in which they become known.</span></p>
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
481100000
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
395100000
CY2021Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
530477000
CY2021Q3 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
1000
CY2021Q3 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
530476000
CY2021Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1466614000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
154000
CY2021Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
956000
CY2021Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1465812000
CY2021Q3 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1997091000
CY2021Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
154000
CY2021Q3 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
957000
CY2021Q3 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1996288000
CY2020Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
773560000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Gains Before Tax
CashEquivalentsGrossUnrealizedGainsBeforeTax
1000
CY2020Q4 crsp Cash Equivalents Gross Unrealized Losses Before Tax
CashEquivalentsGrossUnrealizedLossesBeforeTax
24000
CY2020Q4 crsp Cash Equivalents Fair Value
CashEquivalentsFairValue
773537000
CY2020Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
521820000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
51000
CY2020Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
158000
CY2020Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
521713000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
1295380000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Gains Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedGainsBeforeTax
52000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Gross Unrealized Losses Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesGrossUnrealizedLossesBeforeTax
182000
CY2020Q4 crsp Cash Equivalents And Available For Sale Debt Securities Fair Value
CashEquivalentsAndAvailableForSaleDebtSecuritiesFairValue
1295250000
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
1028900000
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
280300000
CY2021Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2020Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2021Q3 crsp Credit Related Impairment Charges For Marketable Securities
CreditRelatedImpairmentChargesForMarketableSecurities
0
crsp Credit Related Impairment Charges For Marketable Securities
CreditRelatedImpairmentChargesForMarketableSecurities
0
CY2021Q3 crsp Debt Securities Available For Sale Securities Remaining Maturity Greater Than Three Year
DebtSecuritiesAvailableForSaleSecuritiesRemainingMaturityGreaterThanThreeYear
0
CY2021Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
138709000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
63335000
CY2021Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32826000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21175000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
105883000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42160000
CY2021Q3 us-gaap Depreciation
Depreciation
5300000
us-gaap Depreciation
Depreciation
11700000
CY2020Q3 us-gaap Depreciation
Depreciation
2300000
us-gaap Depreciation
Depreciation
6600000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17027000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22402000
CY2021Q3 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
36316000
CY2020Q4 crsp Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
21684000
CY2021Q3 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
97000
CY2020Q4 crsp Accrued License Fees Current
AccruedLicenseFeesCurrent
1401000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3567000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1670000
CY2021Q3 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
5042000
CY2020Q4 crsp Accrued Intellectual Property Costs Current
AccruedIntellectualPropertyCostsCurrent
3625000
CY2021Q3 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
5922000
CY2020Q4 crsp Accrued Property And Equipment
AccruedPropertyAndEquipment
2835000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
332000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
165000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
68303000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
53782000
crsp Joint Venture Agreement Date
JointVentureAgreementDate
2015-12-19
CY2021Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
6784000
CY2021Q3 crsp Prepaid Expenses And Other Current Assets Fair Value Disclosure
PrepaidExpensesAndOtherCurrentAssetsFairValueDisclosure
2565000
CY2021Q3 us-gaap Property Plant And Equipment Fair Value Disclosure
PropertyPlantAndEquipmentFairValueDisclosure
9340000
CY2021Q3 crsp Operating Lease Assets Fair Value Disclosure
OperatingLeaseAssetsFairValueDisclosure
11003000
CY2021Q3 crsp Restricted Cash Fair Value Disclosure
RestrictedCashFairValueDisclosure
1226000
CY2021Q3 crsp Accrued Expenses And Other Current Liabilities Fair Value Disclosure
AccruedExpensesAndOtherCurrentLiabilitiesFairValueDisclosure
3915000
CY2021Q3 crsp Operating Lease Liabilities Fair Value Disclosure
OperatingLeaseLiabilitiesFairValueDisclosure
11003000
CY2021Q3 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
16000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.03
CY2021Q3 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
80321227
CY2020Q4 crsp Common Stock Registered Share Capital
CommonStockRegisteredShareCapital
75133951
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
145364335
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115172786
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26199000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17240000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76622000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
47088000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8101980
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
42.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1130158
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
136.22
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
964436
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
33.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
379930
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
65.84
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7887772
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
55.89
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4374086
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
37.27
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
7887772
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
55.89
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
159200000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-127153000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-92439000
us-gaap Net Income Loss
NetIncomeLoss
518909000
us-gaap Net Income Loss
NetIncomeLoss
-241826000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
76288534
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70143481
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75712437
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
64159224
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
76288534
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70143481
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
80554682
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
64159224
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.67
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.32
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.77
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.67
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.32
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.44
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.77
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8911688
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8842224
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1706783
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8842224
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4100000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.008
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000000.0
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.004

Files In Submission

Name View Source Status
0000950170-21-002825-index-headers.html Edgar Link pending
0000950170-21-002825-index.html Edgar Link pending
0000950170-21-002825.txt Edgar Link pending
0000950170-21-002825-xbrl.zip Edgar Link pending
crsp-20210930.htm Edgar Link pending
crsp-20210930.xsd Edgar Link pending
crsp-20210930_cal.xml Edgar Link unprocessable
crsp-20210930_def.xml Edgar Link unprocessable
crsp-20210930_htm.xml Edgar Link completed
crsp-20210930_lab.xml Edgar Link unprocessable
crsp-20210930_pre.xml Edgar Link unprocessable
crsp-ex31_1.htm Edgar Link pending
crsp-ex31_2.htm Edgar Link pending
crsp-ex32_1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending